菌状息肉腫治療法の世界市場:小分子、生物製剤

LINEで送る

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Small molecules – Market size and forecast 2018-2023

Biologics – Market size and forecast 2018-2023

Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Strong R&D of pipeline molecules

Novel drug delivery system

Increasing research funding

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Azurity Pharmaceuticals Inc.

Celgene Corp.

Eisai Co. Ltd.

Helsinn Healthcare SA

Horizon Therapeutics Plc

Kyowa Kirin Co. Ltd.

Merck & Co. Inc.

Seattle Genetics Inc.

Soligenix Inc.

Takeda Pharmaceutical Co. Ltd.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market characteristics analysis

Exhibit 06: Market segments

Exhibit 07: Market definition – Inclusions and exclusions checklist

Exhibit 08: Market size 2018

Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 11: Five forces analysis 2018

Exhibit 12: Five forces analysis 2023

Exhibit 13: Bargaining power of buyers

Exhibit 14: Bargaining power of suppliers

Exhibit 15: Threat of new entrants

Exhibit 16: Threat of substitutes

Exhibit 17: Threat of rivalry

Exhibit 18: Market condition – Five forces 2018

Exhibit 19: Global mycosis fungoides therapeutics market pipeline: Overview

Exhibit 20: Global mycosis fungoides therapeutics market pipeline: Snapshot

Exhibit 21: Type – Market share 2018-2023 (%)

Exhibit 22: Comparison by type

Exhibit 23: Small molecules – Market size and forecast 2018-2023 ($ millions)

Exhibit 24: Small molecules – Year-over-year growth 2019-2023 (%)

Exhibit 25: Biologics – Market size and forecast 2018-2023 ($ millions)

Exhibit 26: Biologics – Year-over-year growth 2019-2023 (%)

Exhibit 27: Market opportunity by type

Exhibit 28: Customer landscape

Exhibit 29: Customer landscape analysis

Exhibit 30: Market share by geography 2018-2023 (%)

Exhibit 31: Geographic comparison

Exhibit 32: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 33: North America – Year-over-year growth 2019-2023 (%)

Exhibit 34: Top 3 countries in North America

Exhibit 35: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 36: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 37: Top 3 countries in Europe

Exhibit 38: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 39: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 40: Top 3 countries in Asia

Exhibit 41: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 42: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 43: Top 3 countries in ROW

Exhibit 44: Key leading countries

Exhibit 45: Market opportunity

Exhibit 46: Decision framework

Exhibit 47: Impact of drivers and challenges

Exhibit 48: Vendor landscape

Exhibit 49: Landscape disruption

Exhibit 50: Vendor landscape analysis

Exhibit 51: Vendors covered

Exhibit 52: Vendor classification

Exhibit 53: Market positioning of vendors

Exhibit 54: Azurity Pharmaceuticals Inc. – Vendor overview

Exhibit 55: Azurity Pharmaceuticals Inc. – Business segments

Exhibit 56: Azurity Pharmaceuticals Inc. – Organizational developments

Exhibit 57: Azurity Pharmaceuticals Inc. – Key offerings

Exhibit 58: Azurity Pharmaceuticals Inc. – Key customers

Exhibit 59: Celgene Corp. – Vendor overview

Exhibit 60: Celgene Corp. – Business segments

Exhibit 61: Celgene Corp. – Organizational developments

Exhibit 62: Celgene Corp. – Geographic focus

Exhibit 63: Celgene Corp. – Key offerings

Exhibit 64: Celgene Corp. – Key customers

Exhibit 65: Eisai Co. Ltd. – Vendor overview

Exhibit 66: Eisai Co. Ltd. – Business segments

Exhibit 67: Eisai Co. Ltd. – Organizational developments

Exhibit 68: Eisai Co. Ltd. – Geographic focus

Exhibit 69: Eisai Co. Ltd. – Segment focus

Exhibit 70: Eisai Co. Ltd. – Key offerings

Exhibit 71: Eisai Co. Ltd. – Key customers

Exhibit 72: Helsinn Healthcare SA – Vendor overview

Exhibit 73: Helsinn Healthcare SA – Business segments

Exhibit 74: Helsinn Healthcare SA – Organizational developments

Exhibit 75: Helsinn Healthcare SA – Key offerings

Exhibit 76: Helsinn Healthcare SA – Key customers

Exhibit 77: Horizon Therapeutics Plc – Vendor overview

Exhibit 78: Horizon Therapeutics Plc – Business segments

Exhibit 79: Horizon Therapeutics Plc – Organizational developments

Exhibit 80: Horizon Therapeutics Plc – Geographic focus

Exhibit 81: Horizon Therapeutics Plc – Segment focus

Exhibit 82: Horizon Therapeutics Plc – Key offerings

Exhibit 83: Horizon Therapeutics Plc – Key customers

Exhibit 84: Kyowa Kirin Co. Ltd. – Vendor overview

Exhibit 85: Kyowa Kirin Co. Ltd. – Business segments

Exhibit 86: Kyowa Kirin Co. Ltd. – Organizational developments

Exhibit 87: Kyowa Kirin Co. Ltd. – Geographic focus

Exhibit 88: Kyowa Kirin Co. Ltd. – Segment focus

Exhibit 89: Kyowa Kirin Co. Ltd. – Key offerings

Exhibit 90: Kyowa Kirin Co. Ltd. – Key customers

Exhibit 91: Merck & Co. Inc. – Vendor overview

Exhibit 92: Merck & Co. Inc. – Business segments

Exhibit 93: Merck & Co. Inc. – Organizational developments

Exhibit 94: Merck & Co. Inc. – Geographic focus

Exhibit 95: Merck & Co. Inc. – Segment focus

Exhibit 96: Merck & Co. Inc. – Key offerings

Exhibit 97: Merck & Co. Inc. – Key customers

Exhibit 98: Seattle Genetics Inc. – Vendor overview

Exhibit 99: Seattle Genetics Inc. – Business segments

Exhibit 100: Seattle Genetics Inc. – Organizational developments

Exhibit 101: Seattle Genetics Inc. – Key offerings

Exhibit 102: Seattle Genetics Inc. – Key customers

Exhibit 103: Soligenix Inc. – Vendor overview

Exhibit 104: Soligenix Inc. – Business segments

Exhibit 105: Soligenix Inc. – Organizational developments

Exhibit 106: Soligenix Inc. – Segment focus

Exhibit 107: Soligenix Inc. – Key offerings

Exhibit 108: Soligenix Inc. – Key customers

Exhibit 109: Takeda Pharmaceutical Co. Ltd. – Vendor overview

Exhibit 110: Takeda Pharmaceutical Co. Ltd. – Business segments

Exhibit 111: Takeda Pharmaceutical Co. Ltd. – Organizational developments

Exhibit 112: Takeda Pharmaceutical Co. Ltd. – Geographic focus

Exhibit 113: Takeda Pharmaceutical Co. Ltd. – Key offerings

Exhibit 114: Takeda Pharmaceutical Co. Ltd. – Key customers

Exhibit 115: Validation techniques employed for market sizing

Exhibit 116: List of abbreviations

Exhibit 117: Definition of market positioning of vendors




※当サイトのレポート紹介カバレッジ
■産業:医療、IT、電子、自動車、産業機械、建設、消費財、食品、化学、材料、エネルギー、金融、サービスなど多様
■地域:世界市場、アジア市場、中国市場、欧州市場、北米市場、中南米市場、中東市場、アフリカ市場など全世界
■レポート種類:市場動向、規模、占有率、トレンド、将来展望、未来予測、業界分析、産業分析、企業分析、事業機会分析、戦略提言など多様